High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.
about
Calcium channel blockers for pulmonary arterial hypertensionCalcium channel blockers for pulmonary arterial hypertensionProstacyclin for pulmonary hypertension in adultsMedical treatment update on pulmonary arterial hypertensionResidual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndromeRight ventricular dysfunction and failure in chronic pressure overload.Density and localization of calcium channels of the L-type in human pulmonary artery.Pulmonary hypertension: diagnosis and managementSildenafil for pulmonary hypertension.Acute oxygen-sensing mechanisms.Pulmonary hypertension in collagen vascular disease.The treatment of primary pulmonary hypertensionProfile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilatorsPulmonary hypertension: its assessment and treatmentIdentifying "super responders" in pulmonary arterial hypertension.Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapiesRegulation of pulmonary vasoconstriction by agonists and caveolae.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine.Severe pulmonary hypertension in Ullrich-Noonan syndrome.Prediction of favourable responses to long term vasodilator treatment of pulmonary hypertension by short term administration of epoprostenol (prostacyclin) or nifedipine.New approaches to pulmonary hypertension.Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension.Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.Bosentan: a dual endothelin receptor antagonist.Prostacyclin for pulmonary hypertension.The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts.Current and emerging therapy for primary pulmonary hypertension.New perspectives for the treatment of pulmonary hypertensionTreatment of pulmonary hypertension: a promising new age.Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension.Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost.Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchangeCellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluidRecommendations on the management of pulmonary hypertension in clinical practice.Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost.Progress in the understanding and management of pulmonary arterial hypertension.Bosentan: a novel agent for the treatment of pulmonary arterial hypertension.Cor pulmonale. Treatment implications of right versus left ventricular impairment.Hypoxic pulmonary hypertension (HPH) and iptakalim, a novel ATP-sensitive potassium channel opener targeting smaller arteries in hypertension.
P2860
Q24187010-99E5AA56-FCF0-4DF5-9052-E030E14C64B3Q24200926-B0EA81A7-76EE-4118-B151-DDC6CED53162Q24246933-A01C6294-3D93-45D5-8C80-32AB5D9B495BQ26785995-32C9CF8B-13C4-40E6-A4EE-3E0FFEE2E87AQ28361795-F2495F74-1339-41E4-A7E5-0473BDE7FB4BQ30475529-97FDA6BB-8D61-4D2B-84DA-F03600638511Q32062325-C528CB05-97A5-4411-96BD-47677A471EC5Q33157071-55C397E2-1451-4F64-8611-3B80882C5858Q33213984-EA255DC8-1D84-4FA6-9BE6-F7A543E0B6A1Q33577287-4CE7C580-A6CB-44D7-A8EF-5E1A06DF0401Q33592469-40607C3E-A7B8-4611-BEC1-DC318DB59371Q33611165-292B7742-0D3E-41D7-A993-B101540533B0Q33613576-E008D9AF-8132-457E-A031-694C4E859A70Q33714015-3EB3BA1E-5D99-429C-9908-6BB547B0C7A7Q33788452-D48D49E1-775D-4870-A178-FF68C99B4F8DQ33849207-386E723E-8FCA-46C6-A1EF-7A3C4649EAB2Q33925116-67C042B7-A863-4842-A31D-A10B1A2CA020Q33965898-42EDDD3F-8C14-4F9C-91BC-3495AFF54808Q33973748-10EC9949-6453-4C89-ABEA-0A9AE59283EAQ34000243-EE41B1F9-341C-41CF-98F3-24E5C8A3CE6EQ34117279-35B301E1-A248-44C4-B6C2-B42823B159C3Q34192441-1F118740-D8AD-48F6-8AA3-37BCAE8AC78EQ34275313-6C73E0E6-2BC8-4C11-B717-828DD4572865Q34631613-46950B85-69C2-427D-96AE-7C99621FA8A2Q34707006-2C11CDF4-815F-4376-99C1-C3D0E84B4723Q34758143-CB9FA56F-E284-4DBE-A0D7-6107648E3F24Q34782476-0FB4EEA6-EC8B-40F6-BE06-F13FF42FED9FQ34796981-4354FD3D-018C-44C7-B449-A09361975551Q34903204-A88E1B01-6D76-4F27-BA55-4F1FA2654A65Q34985847-D644C8A4-02B3-4D32-B7F7-AE568040A6FFQ35019516-8F120833-D1E3-4A1E-8236-E75885078E64Q35366592-63ED434A-9271-48B2-8009-035DE8493A78Q35563477-020E7F37-0F8F-4826-8EDD-FE298C3B9549Q35563480-3676CC55-0C16-46D3-8E51-4144F9F8C4D6Q35578998-0E80F1D9-D006-4CF0-BD7B-7BDB6CCF8595Q35581973-C5D22C47-A124-4F89-88CC-87E9DA903382Q35662646-1B0B21FE-2CA2-4966-98BD-9F15AE89D27DQ35680206-CEAE5138-F5F8-4E3E-A8D8-235655B4E905Q36082358-DE12D5B0-1DD8-4354-92E5-1E4789DCB77EQ36449206-C62F97EA-4051-47D9-996A-1108C706CE5B
P2860
High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
High-dose calcium channel-bloc ...... right ventricular hypertrophy.
@en
High-dose calcium channel-bloc ...... right ventricular hypertrophy.
@nl
type
label
High-dose calcium channel-bloc ...... right ventricular hypertrophy.
@en
High-dose calcium channel-bloc ...... right ventricular hypertrophy.
@nl
prefLabel
High-dose calcium channel-bloc ...... right ventricular hypertrophy.
@en
High-dose calcium channel-bloc ...... right ventricular hypertrophy.
@nl
P356
P1433
P1476
High-dose calcium channel-bloc ...... right ventricular hypertrophy.
@en
P2093
P304
P356
10.1161/01.CIR.76.1.135
P407
P577
1987-07-01T00:00:00Z